Team:Virginia/Project Overview

From 2013.igem.org

(Difference between revisions)
 
(24 intermediate revisions not shown)
Line 86: Line 86:
width:900px;
width:900px;
         padding-bottom: 10px;
         padding-bottom: 10px;
-
}
 
-
#groupbio {
 
-
width: 950px;
 
-
margin-right: auto;
 
-
margin-left:auto;
 
-
line-height: 1.7 em;
 
-
        font-size:17px;
 
-
        border: 3px solid rgba(255,255,255,0.3);
 
-
        padding: 10px;
 
}
}
.topbanner {
.topbanner {
Line 190: Line 181:
#menu11 ul li:hover span.text a{
#menu11 ul li:hover span.text a{
     text-decoration:none;
     text-decoration:none;
-
color:#2B60DE;
+
color:#66CCFF;
 +
}
 +
#btext {
 +
clear:both;
 +
position:relative;
 +
z-index:1;
 +
        background-color: #000000;
 +
        padding:55px;
 +
margin-right: auto;
 +
margin-left:auto;
 +
line-height: 2 em;
 +
        font-size:17px;
 +
color:#FFFFFF;
 +
}
 +
#groupbio {
 +
width: 950px;
 +
margin-right: auto;
 +
margin-left:auto;
 +
line-height: 1.7 em;
 +
        font-size:17px;
 +
        border: 1px solid rgba(255,255,255,0.3);
 +
        padding: 10px;
 +
}
 +
#groupbio span {
 +
font-size:20px;
 +
text-decoration:underline;
 +
padding-top:50px;
}
}
</style>
</style>
Line 219: Line 236:
                 <p><a href="https://2013.igem.org/Team:Virginia/Results">Results</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Results">Results</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Modeling">Modeling</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Modeling">Modeling</a></p>
-
                 <p><a href="https://2013.igem.org/Team:Virginia/Applications">Applications</a></p></span>
+
                 <p><a href="https://2013.igem.org/Team:Virginia/Software">Software</a></p>
 +
 
 +
                <p><a href="https://2013.igem.org/Team:Virginia/Chassis_Improvements">Chassis Improvements</a></p></span>
         </li>
         </li>
         <li>
         <li>
Line 230: Line 249:
         </li>
         </li>
         <li>
         <li>
-
                <span class="title">Human Practices</span>
+
                          <span class="title">Human Practices</span>
                 <span class="text">
                 <span class="text">
                 <p><a href="https://2013.igem.org/Team:Virginia/Human_Practices_Overview">Overview</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Human_Practices_Overview">Overview</a></p>
-
                 <p><a href="https://2013.igem.org/Team:Virginia/Public_Perception">Public Perception</a></p>
+
                 <p><a href="https://2013.igem.org/Team:Virginia/Safety Considerations">Safety Considerations</a></p>
-
                 <p><a href="https://2013.igem.org/Team:Virginia/Relevance">Relevance</a></p>
+
                 <p><a href="https://2013.igem.org/Team:Virginia/High_School_Education_Series">High School Education Series</a></p>
-
          <p><a href="https://2013.igem.org/Team:Virginia/Outreach">Outreach</a></p></span>
+
                <p><a href="https://2013.igem.org/Team:Virginia/Documentary">Documentary</a></p>
 +
                <p><a href="https://2013.igem.org/Team:Virginia/Media_Coverage">Media Coverage</a></p>
 +
</span>
         </li>
         </li>
         <li>
         <li>
Line 244: Line 265:
                 <p><a href="https://igem.org/Team.cgi?year=2013&team_name=Virginia">Profile</a></p>
                 <p><a href="https://igem.org/Team.cgi?year=2013&team_name=Virginia">Profile</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Sponsors">Sponsors</a></p>
                 <p><a href="https://2013.igem.org/Team:Virginia/Sponsors">Sponsors</a></p>
-
       <p><a href="https://2013.igem.org/Team:Virginia/Collaboration">Collaboration</a></p></span></li></ul></div></div>
+
       <p><a href="https://2013.igem.org/Team:Virginia/Attributions">Attributions</a></p></span></li></ul></div></div>
<div class="body">
<div class="body">
-
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Uneven cellular division in bacteria can yield a normal parent cell and an achromosomal “minicell”. At 400 nm, <i>E. coli</i> minicells are much smaller than their parental cells. Their lack of chromosomal DNA renders them unable to replicate and cause infection, yet they still retain and express plasmid genes (Mugridge). Additionally, minicells have stable, non-leaky membranes and inherit the cytosolic composition of their parent cell, maintaining the same protein and ion concentrations (Frazer). Since their plasma membranes are derived from the parent cell, minicells also retain any targeting systems put in place before their production. Perhaps the best complements to minicells’ modularity, membrane-bound antibodies enable highly-specific and effective targeting of minicells to specific cells (MacDiarmid). These unique qualities make minicells a viable and safer alternative to comparable chassis such as liposomes and standard <i>E. coli</i>.
+
<div id="groupbio">
-
</p>
+
<div id="btext">
-
 
+
<span><u>Project Overview</u></span>
-
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Minicells hold great potential in a synthetic biology context. We aim to create a standard BioBrick that induces minicell formation in <i>E. coli</i> cells and to design additional safeguards to make our chassis as safe as possible. Research has shown that the overproduction of the tubulin-homolog FtsZ leads to minicell formation (Ward). Accordingly, we designed a simple BioBrick to contain the <i>ftsz</i> gene under the control of an IPTG-inducible promoter. This allows us to adjust FtsZ production to achieve optimal minicell production. We are simultaneously developing a quantitative model that relates the amount of IPTG added to the final concentration of minicells that are produced and purified.
+
<br><br>
-
</p>
+
<p><u> Opportunity: Synthesizing a Better Drug Delivery Vector </u></p>
-
 
+
<p> <p style="text-indent: 5em;">Every freely administered drug causes side effects. Cancer is a classic example. Because of off-target toxicity, many cancer patients have to hope that their chemotherapy kills their cancer before it kills them. </p>
-
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite minicells’ inability to replicate, their safety for medicinal use remains an utmost concern. To address this, we seek to reduce— or even eliminate— the threat of an inflammatory response induced through the presence of lipopolysaccharide (LPS) and via complement deposition. The Ail protein from Yersinia pestis is especially promising in that regard, as it confers resistance to the human innate immune response (Kolodziejek). We have also explored the possibility of encapsulating our chassis with polysialic acid, mimicking the mammalian structures typically associated with the neural cell adhesion molecule (NCAM). Sialylation would further reduce complement deposition, as well as antibody opsonization. In other words, both Ail and polysialic acid can be produced in concert with our original FtsZ BioBrick to create safer minicells in a desired strain of <i>E. coli</i>. As an additional safety precaution, we also decided to use the <i>lpxM</i> mutant strain, which has a reduction in the acyl-group modifications of the conserved Lipid A portion of its LPS. Studies have shown that this variant can reduce E-selectin stimulation and TNF-α production by up to 10,000-fold (Anisimov). Combined, these three safeguards could hence significantly slash the immunogenicity and risks associated with a minicell chassis.
+
<p style="text-indent: 5em;"> Many drug delivery nano-vectors have been developed to address this issue. However, most have severely limiting disadvantages. For example, liposomes, the vector projected to have the largest market share in the next ten years, are often expensive to produce and leaky in functionality. </p>
-
</p>
+
<p><p style="text-indent: 5em;">Bacteria have several properties that would make them an interesting alternative drug delivery vectors.  
-
 
+
<ul><li>Their surface membranes can be modified for targeting </li>
-
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In conclusion, minicells lack the ability to replicate and therefore carry virtually no risk of infection, which is especially important for the young, the elderly, or the immunocompromised. The Ail, polysialic acid and <i>IpxM</i> mutant modifications we will implement will further enhance their innate safety, lowering associated health risks. By combining multiple safety elements with an inherent ease of production and modularity, we hope to showcase minicells' potential as a chassis for widespread therapeutic use and consumption.
+
<li>Biological and can accommodate Biobricks </li>
-
</p>
+
<li>Easily grown and manufactured, unlike many other drug delivery vectors. </li>
-
 
+
</ul></p>  
-
<p><b>Sources</b></p>
+
<br>
-
<p>Anisimov, A., Shalkhutdinova, R., Pan, L., Feodorova, V., Savostina, E., Bystrova, O., Lindner, B., & Mokrievich, A. (2007). Effect of deletion of the lpxm gene on virulence and vaccine potential of yersinia pestis in mice. Journal of Medical Microbiology, 56(4), 443-53. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17374882?dopt=AbstractPlus </p>
+
<p style="text-indent: 5em;"> Unfortunately, as in the case of many potential synthetic biology applications, the utility of bacteria as vectors is limited by safety concerns. Our initial investigation on this problem led us to a forgotten discovery from the 1950’s—the bacterial minicell. </p>
-
 
+
<p style="text-indent: 5em;"> Minicells are small, achromosomal products of aberrant cell division. Because they lack chromosomes , they cannot replicate, mutate, or express virulent bacteria genes. However, they still express transfected plasmids, which means that minicells remain fully compatible with standardized biobrick parts. While largely neglected for decades, minicells are only now resurfacing, in the wake of the recent, explosive growth of the modern biotechnology industry. This past summer, we engineered the bacterial minicell into a safe, alternative chassis for drug delivery applications. </p>
-
<p>Frazer, A. & Curtiss, 3rd R. (1975). Production, properties and utility of bacterial minicells. Current Topics in Microbiology and Immunology. 69, 1–84.</p>
+
</div></div></div>
-
 
+
-
<p>Kolodziejek, A., Schnider, D., Rohde, H., Wojtowicz, A., Bohach, G., Minnich, S., & Hovde, C. (2010). Outer membrane protein x (ail) contributes to yersinia pestis virulence in pneumonic plague and its activity is dependent on the lipopolysaccharide core length. Infectious Immunology, 78(12), 5233-43. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20837715</p>
+
-
 
+
-
<p>MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., et al. (2007). Bacterially derived 400 nm particles for encapsulation and cancer cells targeting of chemotherapeutics. Cancer Cell, 11(5), 431-45. </p>
+
-
 
+
-
<p>Ward, J.E., Lutkenhaus, J. (1985). Overproduction of FtsZ induces minicell formation in Escherichia-coli. Cell, 42(3), 941-9.
+
-
</p>
+
-
 
+
-
 
<div class="footer">  
<div class="footer">  
   <h3>&nbsp;</h3>
   <h3>&nbsp;</h3>

Latest revision as of 01:54, 29 October 2013

VGEM Welcomes You!

Project Overview

Opportunity: Synthesizing a Better Drug Delivery Vector

Every freely administered drug causes side effects. Cancer is a classic example. Because of off-target toxicity, many cancer patients have to hope that their chemotherapy kills their cancer before it kills them.

Many drug delivery nano-vectors have been developed to address this issue. However, most have severely limiting disadvantages. For example, liposomes, the vector projected to have the largest market share in the next ten years, are often expensive to produce and leaky in functionality.

Bacteria have several properties that would make them an interesting alternative drug delivery vectors.

  • Their surface membranes can be modified for targeting
  • Biological and can accommodate Biobricks
  • Easily grown and manufactured, unlike many other drug delivery vectors.


Unfortunately, as in the case of many potential synthetic biology applications, the utility of bacteria as vectors is limited by safety concerns. Our initial investigation on this problem led us to a forgotten discovery from the 1950’s—the bacterial minicell.

Minicells are small, achromosomal products of aberrant cell division. Because they lack chromosomes , they cannot replicate, mutate, or express virulent bacteria genes. However, they still express transfected plasmids, which means that minicells remain fully compatible with standardized biobrick parts. While largely neglected for decades, minicells are only now resurfacing, in the wake of the recent, explosive growth of the modern biotechnology industry. This past summer, we engineered the bacterial minicell into a safe, alternative chassis for drug delivery applications.

 

Contact

Questions? Comments? Email us at virginia.igem@gmail.com

 

Retrieved from "http://2013.igem.org/Team:Virginia/Project_Overview"